Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has no clinically significant findings on a physical examination and clinical laboratory tests~* Female patients of childbearing potential must agree to use one of the following methods of birth control:~  1. Hormonal contraception~ 2. Double-barrier birth control~ 3. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy~* Patient meets protocol criteria for diagnosis of IBS-C~* Patient demonstrates continued IBS-C symptoms through Pretreatment Period~* Patient maintains a minimum level of compliance with daily diary~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Linaclotide 290 µg (Type: EXPERIMENTAL): Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).